A prospective, open-label study evaluating rifabutin safety and plasma pharmacokinetics among TB/HIV coinfected children 3–15 years of age receiving rifabutin 2.5 mg/kg daily with standard doses of lopinavir/ritonavir
Latest Information Update: 24 Dec 2020
At a glance
- Drugs Rifabutin (Primary) ; Lopinavir/ritonavir
- Indications Mycobacterium avium complex infections
- Focus Pharmacokinetics
- 24 Dec 2020 New trial record
- 09 Dec 2020 Primary endpoint (rifabutin AUC024) has not been met as per results published in the Journal of Antimicrobial Chemotherapy
- 09 Dec 2020 Results published in the Journal of Antimicrobial Chemotherapy